Compare

Gyre Therapeutics/$GYRE

1D1W1M3M6MYTD1Y5YMAX

About Gyre Therapeutics

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Ticker
$GYRE
Sector
Health
Primary listing
NASDAQ
Employees
625
Headquarters
San Diego, United States
Website
www.gyretx.com

GYRE Metrics

BasicAdvanced
$471M
-
-$0.22
4.83
-

Bulls say / Bears say

F351 met its Phase 3 primary endpoint for chronic hepatitis B-related liver fibrosis, and China’s regulator accepted its NDA for priority review. Approval could give Gyre a second fibrosis product to sell through its established China network. (Gyre Therapeutics, SEC)
ETUARY sales rose to $28.0 million in the second quarter from $23.5 million a year earlier, and Gyre reaffirmed its 2026 revenue guidance of $100.5–$111.0 million. That commercial base can help support development spending while the company pursues new products. (Gyre Therapeutics)
Gyre has other potential growth drivers beyond its current products: its pirfenidone trial for pneumoconiosis has completed enrolment, and the Cullgen acquisition added a pipeline of targeted protein degraders and antibody-drug conjugates. These programmes broaden the company’s opportunities if clinical development succeeds. (Gyre Therapeutics, Gyre Therapeutics)
The latest reported half-year showed revenue falling to $53.5 million from $60.3 million, while the operating loss widened to $33.3 million from near break-even a year earlier. Higher research costs and transaction expenses add pressure as Gyre invests in its pipeline. (SEC)
Sales are heavily reliant on ETUARY: it generated $28.0 million of the $29.1 million in second-quarter revenue. Meanwhile, China’s centralised procurement programme weighed on sales of Contiva and Etorel, exposing how concentrated the commercial base remains. (Gyre Therapeutics)
The new degrader programmes are still in development, and Gyre’s chief executive said global development requires a different financing need. That creates execution and funding risk before the acquired pipeline can produce meaningful sales. (Investing.com, SEC)
Data summarised monthly by Lightyear AI. Last updated on 14 Oct 2026.

GYRE Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

GYRE Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing GYRE

Funds
Fund name
Fund size
$GYRE weighting
SPDR Russell 2000 US Small Cap€R2US
$5.3B0.00%
SPDR Russell 2000 US Small Cap£R2SC
$5.3B0.00%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.